FindMyKOL
Clinical trialNCT04316637AvailableExpanded Access

Early Access Program With Arimoclomol in US Patients With NPC

SponsorZevraDenmarkNiemann-Pick Disease, Type C
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

NPC is a rare, relentlessly progressive, neurological disease and associated with serious morbidity and shortened life expectancy. The purpose of this Expanded Access Program is to provide early access to arimoclomol for patients with Niemann-Pick Type C disease who, in the opinion and the clinical judgement of the treating physician, may benefit from treatment with arimoclomol. Participants will receive treatment with arimoclomol until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason.

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama Birmingham

    Birmingham, Alabama, United States

    Joy Dean, MD
    Available
  • Ucsf Benioff Children'S Hospital and Research Center/ Ucsf

    Oakland, California, United States

    Caroline Hastings, MD
    Available
  • Children'S Hospital of Orange County (choc)

    Orange, California, United States

    Raymond Wang, MD
    Available
  • Nicklaus Children'S Hospital

    Miami, Florida, United States

    Paula Schleifer, MD
    Available
  • Rush University Medical Center

    Chicago, Illinois, United States

    Elizabeth Berry-Kravis, MD, PhDKatherine J Friedmann, MD
    Available
  • Boston Childrens Hospital

    Boston, Massachusetts, United States

    Melinda Palma, MDOlaf Bodamer, MD
    Available
  • Mayo Clinic Children'S Center

    Rochester, Minnesota, United States

    Marc Patterson, MD, PhD
    Available
  • New York University School of Medicine

    New York, New York, United States

    Nicolas Abreu, MD
    Available
  • Cincinnati Children'S Hospital Medical Center (cch)

    Cincinnati, Ohio, United States

    Nancy Leslie, MD
    Available
  • Children'S Hospital of Philadelphia

    Philadelphia, Pennsylvania, United States

    Can Ficicioglu, MD, PhD
    Available
  • Upmc Children'S Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, United States

    Damara Ortiz, MD
    Available
  • Dell Children'S Medical Center

    Austin, Texas, United States

    Kristina Julich, MD
    Available
  • Ut Health / Mcgovern Medical School; Division of Medical Genetics

    Houston, Texas, United States

    Paul Hillman, MD
    Available

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Arimoclomol
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
—
Last update posted
16 Aug 2024
Registered enrollment
—
Registry id
NCT04316637

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.